Carregant...
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries
Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mechanisms to improve affordability of such...
Guardat en:
| Publicat a: | J Mark Access Health Policy |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Routledge
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5998770/ https://ncbi.nlm.nih.gov/pubmed/29915664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20016689.2018.1478539 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|